Name: China Manufacturer Supply High Quality Wholesale Price Potassium Oxonate CAS 2207-75-2
Brand: Wuhan Fortuna Chemical Co., Ltd.

Specifications of Potassium Oxonate CAS 2207-75-2

Items	Specifications	Results
Appearance	White or off white powder	White or off white powder
Identification	1) UV 2) IR 3) Yield positive reaction	Conforms Conforms Yield positive reaction
Related substances	Total impurities ≤1.0% Individual impurity ≤0.5%	0.31% 0.12%
Assay(HPLC)	≥98.5%	99.7%
Heavy metals	≤20 ppm	Conforms
Loss on Drying	≤1.0 %	0.36%
Conclusion	This product complies with the specifications.

Parameters of Potassium Oxonate CAS 2207-75-2

Product parameters
Cas number:	2207-75-2
Appearance:	White to off-white crystalline powder
Purity:	98.5%min
Package details:	1kg/foil bag;25kg/drum
Brand:	Fortunachem

Potassium oxonate is a chemical compound that plays a specialized and crucial role in cancer chemotherapy. It is not an anti-cancer drug itself but is used as a protective agent to reduce the severe side effects of a common chemotherapy drug called 5-Fluorouracil (5-FU). Its primary purpose is to make chemotherapy more tolerable for patients without reducing its effectiveness against cancer cells.

The Problem: 5-FU's Side Effects

To understand Potassium oxonate's role, we must first look at the drug it helps. 5-FU is a widely used and effective chemotherapy agent for cancers of the gastrointestinal tract (e.g., stomach, colorectal), breast, and pancreas. However, it has a major drawback: it causes severe gastrointestinal (GI) toxicity.

This happens because 5-FU works by inhibiting rapidly dividing cells, a hallmark of cancer. Unfortunately, the cells lining the digestive tract also divide rapidly and are therefore highly vulnerable to 5-FU. This damage leads to debilitating side effects, most notably:

Severe diarrhea
Nausea and vomiting
Mouth sores (stomatitis)
Loss of appetite

These side effects can be so severe that they require dose reduction or delays in treatment, compromising the therapy's overall effectiveness.

How Potassium Oxonate Works: A Targeted Shield

Potassium oxonate addresses this problem through a clever mechanism of localized protection.

The Target Enzyme: In the body, an enzyme called uridine phosphorylase is present in high concentrations in the gastrointestinal tract. This enzyme is responsible for activating 5-FU into its toxic form at the site of the GI tract.
The Inhibition: Potassium oxonate is a potent inhibitor of uridine phosphorylase. When administered alongside 5-FU, it blocks this enzyme's activity specifically within the cells of the intestines.
The Result: By inhibiting the enzyme, Potassium oxonate prevents the activation of 5-FU in the GI tract. This means the chemotherapy drug cannot damage the healthy cells lining the intestines, thereby significantly reducing the incidence and severity of diarrhea and other GI toxicities.

Crucially, because Potassium oxonate's action is localized to the gut (it does not easily enter the bloodstream), it does not interfere with 5-FU's anti-cancer activity in the rest of the body. The drug is still activated by other mechanisms in the tumor cells themselves.

Clinical Application: The S-1 Combination Drug

Potassium oxonate is not used alone. It is a key component of a modern, combination chemotherapy drug known as S-1 (brand names include Teysuno). This oral tablet is a fixed-dose combination of three agents:

Tegafur: A prodrug that is converted into 5-FU slowly in the body, providing a continuous, sustained release of the chemotherapy.
Gimeracil: A different enzyme inhibitor that helps maintain higher levels of 5-FU in the blood and tumors, enhancing its anti-cancer effect.
Oteracil (Potassium oxonate): This is the form of Potassium oxonate used in the drug, and it serves the protective role described above.

This triple combination creates a more effective and far more tolerable chemotherapy regimen. S-1 is a standard treatment for gastric (stomach) cancer in Asia and is also used for pancreatic, colorectal, and other cancers.

Summary

In essence, Potassium oxonate is a chemoprotective agent. Its strategic use in combination chemotherapy regimens like S-1 exemplifies a key goal in modern oncology: to improve the therapeutic index of cancer drugs—that is, to maximize the anti-tumor effect while minimizing harmful side effects, ultimately leading to better patient outcomes and quality of life during treatment.